BOSTON, April 10, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is developing the leading platform for cell programming and biosecurity, today announced the expansion of its strategic partnership with global healthcare leader Novo Nordisk under a framework agreement that initially is contemplated to run over five years.  Novo Nordisk Novo Nordisk and Ginkgo have created a flexible and scalable new model for their R&D partnership. Together, the partners aim to improve the manufacturing of Novo ...